Affiliate Scientist Division of Advanced Diagnostics - Infection & Immunity Toronto General Research Institute (TGRI)
Keywords: myeloma, molecular cytogenetics, prognostic factors, small molecule inhibitors
Multiple myeloma (MM) is a tumour resulting from clonal expansion of plasma cells and constitutes 10% of hematological malignancies. Survival times in MM are very heterogeneous amongst subgroups with different genetic profiles. The primary focus of my lab is to characterize the genomic aberrations responsible for the initiation and progression of MM, and to identify genetic risk factors that predict clinical outcome in MM patients as well as potential molecular targets for future therapy.
In preclinical studies, we investigate small molecule inhibitors that disrupt p53-MDM2 interactions and induce apoptosis in myeloma cells. We also evaluate novel small molecules that can change the conformation of a mutant p53 to a functional wild-type p53, restoring p53 function as a novel therapeutic strategy, particularly in high-risk MM patients harboring p53 deletions/mutations.
Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto.